CDC/MMWR Watch [to 25 October 2014]
Ebola Outbreak – 2014
:: CDC Announces Active Post-Arrival Monitoring for Travelers from Impacted Countries – Press Release WEDNESDAY, OCTOBER 22, 2014
:: CDC update on Ebola Response, 10-22-2014 – Media Advisory WEDNESDAY, OCTOBER 22, 2014
:: Innovative Response by Firestone Health Officials May Have Limited Ebola Spread in a Part of Liberia – Press Release TUESDAY, OCTOBER 21, 2014
:: CDC update on Ebola Response and PPE: 10-20-2014 – Transcript MONDAY, OCTOBER 20, 2014
:: Tightened Guidance for U.S. Healthcare Workers on Personal Protective Equipment for Ebola – Fact Sheet – Media StatementMONDAY, OCTOBER 20, 2014
MMWR October 24, 2014 / Vol. 63 / No. 42
:: Control of Ebola Virus Disease —Firestone District, Liberia, 2014
NIH Watch [to 25 October 2014]
:: Texas nurse free of Ebola virus; discharged from NIH Clinical Center
October 24, 2014 — NIH Clinical Center discharges Nina Pham who is free of Ebola virus disease.
:: NIH media briefing on discharge of Ebola patient from its Clinical Center Special Clinical Studies Unit
October 24, 2014 — NIH officials will brief reporters about the discharge of Nina Pham.
:: NIH begins early human clinical trial of VSV Ebola vaccine
October 22, 2014 — Researchers at NIAID are conducting the early phase trial to evaluate the vaccine, called VSV-ZEBOV.
European Medicines Agency Watch [to 25 October 2014]
:: EMA ready to start assessment of Ebola vaccines and treatments as soon as data are made available
Rapid scientific advice to speed up development
During the past months, the European Medicines Agency (EMA) has put in place a system to give the best possible scientific advice to companies that are currently developing possible vaccines and/or treatments to fight Ebola virus disease.
The Agency has also established a form of rolling review that allows experts to continuously assess incoming data and develop increasingly robust scientific opinions based on the additional data provided during the process. The initial review and subsequent updates will be shared with healthcare decision-makers in the most affected and other countries. This will enable them to take informed decisions on whether and how they want to use the vaccines/medicines in the current Ebola outbreak taking into account their specific situation.
“We are ready and keen to assess data as soon as companies start submitting them,” explains EMA Executive Director Guido Rasi. “We have put in place regulatory processes that allow the best experts from across Europe to accelerate the assessment of data once we receive them.”…
:: Speeding up development of Ebola treatments and vaccines
EMA encourages companies to apply for orphan designation
The European Medicines Agency (EMA) encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Medicines with recognised orphan status have access to a range of incentives to stimulate development and facilitate placing on the market. This includes free scientific advice from EMA, fee waivers and 10 years of market exclusivity once the medicine is authorised.
Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation…